咪唑并[1,2-A]吡啶-7-碳酰肼 | 421595-78-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 咪唑并[1,2-A]吡啶-7-碳酰肼
• 英文名称: imidazo[1,2-a]pyridine-7-carbohydrazide
• CAS: 421595-78-0
• 化学式: C₈H₈N₄O
• mdl: MFCD13183226
• 分子量: 176.178
• InChiKey: VXJBLZXLLRYHPD-UHFFFAOYSA-N

物化性质

• 熔点：
  258-261℃
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-A]吡啶-7-碳酰肼 在 盐酸 、 四氯化碳 、 sodium hydroxide 、 三乙胺 、 sodium nitrite 作用下， 以 乙腈 为溶剂， 反应 37.5h， 生成 N-(triphenyl-λ⁵-phosphanylidene)imidazo[1,2-a]pyridin-7-amine
  参考文献：
  名称：

  Aminoimidazo[1,2-a]pyridines: regioselective synthesis of substituted imidazonaphthyridines, azacarbolines and cyclazines

  摘要：

  In order to study the regioselectivity of thermal cyclocondensation, aminoimidazo [1,2-a]pyridines (AIP) 5a-e were prepared, further converted into iminophosphoranes 7a-e, and ultimately converted regioselectively in angular annulated imidazonaphthyridines (IN) 8a, 10a, 11a, 12a or linear annulated dipyridoimidazole (DPI) 17a. From 2-substituted derivative 23, the peri annulated product 24a was obtained. The starting amines 5a-f reacted with aldehydes to yield regioselectively IN 8a-c, 10a-c, 11a-c, 12a,b, DPI 16a-e, 17a-d and TIBO like structures (+/-)-13 and 24a-c, as proved by X-ray analysis. The 1,2- or 1,4-addition between amines and alpha,beta-unsaturated aldehydes concerning the pyridine and imidazole moieties is discussed in the light of these results. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(01)01141-3
• 作为产物：
  描述：

  2-氨基异烟酸乙酯 在 碳酸氢钠 、 一水合肼 作用下， 以 乙醇 、 水 为溶剂， 反应 69.0h， 生成 咪唑并[1,2-A]吡啶-7-碳酰肼
  参考文献：
  名称：

  Aminoimidazo[1,2-a]pyridines: regioselective synthesis of substituted imidazonaphthyridines, azacarbolines and cyclazines

  摘要：

  In order to study the regioselectivity of thermal cyclocondensation, aminoimidazo [1,2-a]pyridines (AIP) 5a-e were prepared, further converted into iminophosphoranes 7a-e, and ultimately converted regioselectively in angular annulated imidazonaphthyridines (IN) 8a, 10a, 11a, 12a or linear annulated dipyridoimidazole (DPI) 17a. From 2-substituted derivative 23, the peri annulated product 24a was obtained. The starting amines 5a-f reacted with aldehydes to yield regioselectively IN 8a-c, 10a-c, 11a-c, 12a,b, DPI 16a-e, 17a-d and TIBO like structures (+/-)-13 and 24a-c, as proved by X-ray analysis. The 1,2- or 1,4-addition between amines and alpha,beta-unsaturated aldehydes concerning the pyridine and imidazole moieties is discussed in the light of these results. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(01)01141-3

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE TYROSINES KINASES RÉCEPTRICES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009150240A1

  公开（公告）日：2009-12-17

  The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及新的双环杂环衍生物化合物，包括含有该化合物的药物组合物，以及利用该化合物治疗疾病，例如癌症。
• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY
  申请人：Saxty Gordon

  公开号：US20120041000A1

  公开（公告）日：2012-02-16

  The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及公式（I）的新的双环杂环基衍生物，涉及包含该类化合物的药物组合物，以及利用该类化合物治疗疾病，例如癌症。
• NOVEL INHIBITORS
  申请人：HEISER Ulrich

  公开号：US20110224259A1

  公开（公告）日：2011-09-15

  The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  本发明涉及新型杂环衍生物，作为谷氨酰环化酶（QC，EC 2.3.2.5）的抑制剂。QC催化N-末端谷氨酰残基的分子内环化成吡咯谷氨酸（5-氧代脯氨酰，pGlu*），释放氨，并将N-末端谷氨酸残基分子内环化成吡咯谷氨酸，释放水。
• IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
  申请人：Berdini Valerio

  公开号：US20120208791A1

  公开（公告）日：2012-08-16

  The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  本发明涉及新的双环杂环衍生物化合物，涉及包含该化合物的药物组合物以及涉及使用该化合物治疗疾病，例如癌症的用途。